← Eichor
Study identifier: NCT07364162 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Exogenous Ketone Supplementation in ICU Delirium

Condition: ICU Delirium · Critical Illness  ·  Sponsor: Vanderbilt University Medical Center

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Delirium is a common syndrome in intensive care unit (ICU) patients. Those experiencing delirium may suddenly feel confused, have trouble thinking clearly, struggle to pay attention, or see and hear things that are not real. Delirium is associated with worse long-term outcomes such as cognitive impairment, depression, and PTSD (post-traumatic stress disorder). This study examines whether an investigational medical-grade ketone supplement drink (ketone monoester \[brand name: Ultrapure Ketone Monoester\]) is safe and feasible to use in ICU patients, and to look for signals that it might reduce delirium or shorten its duration compared to a volume-, taste-, and calorie-matched placebo.

This description comes directly from the study's public registry record.

Talk to the study team

Ryan J Smith, MD, JD  ·  (602) 538-5003  ·  ryan.j.smith@vumc.org

Rebecca Abel, MA  ·  6158753763  ·  wes.ely@vumc.org

Always discuss trial participation with your own doctor first.

Locations (1)

Vanderbilt University Medical CenterNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07364162